Cao Mingming, Song Wenjing, Liang Runyu, Teng Lili, Zhang Mei, Zhang Jiyao, Zhu Luwen
Heilongjiang University of Chinese Medicine, 24 Heping Road, Xiangfang District, Heilongjiang, Harbin 150040, China.
Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, 411 Guogeli Street, Nangang District, Heilongjiang, Harbin 150001, China.
Int J Genomics. 2021 Nov 20;2021:9098145. doi: 10.1155/2021/9098145. eCollection 2021.
Ischemia-reperfusion (I/R) injury is a progressive injury that aggravates the pathological state when the organ tissue restores blood supply after a certain period of ischemia, including the myocardial, brain, liver, kidney, and intestinal. With growing evidence that microRNAs (miRNAs) play an important role as posttranscription gene silencing mediators in many I/R injury, in this review, we highlight the microRNAs that are related to I/R injury and their regulatory molecular pathways. In addition, we discussed the potential role of miRNA as a biomarker and its role as a target in I/R injury treatment. Developing miRNAs are not without its challenges, but prudent design combined with existing clinical treatments will result in more effective therapies for I/R injury. This review is aimed at providing new research results obtained in this research field. It is hoped that new research on this topic will not only generate new insights into the pathophysiology of miRNA in I/R injury but also can provide a basis for the clinical application of miRNA in I/R.
缺血再灌注(I/R)损伤是一种进行性损伤,当器官组织在经历一定时间的缺血后恢复血液供应时,会加重病理状态,包括心肌、脑、肝、肾和肠道。越来越多的证据表明,微小RNA(miRNA)作为转录后基因沉默介质在许多I/R损伤中发挥重要作用。在本综述中,我们重点介绍了与I/R损伤相关的微小RNA及其调控分子途径。此外,我们还讨论了miRNA作为生物标志物的潜在作用及其在I/R损伤治疗中作为靶点的作用。开发miRNA并非没有挑战,但谨慎的设计与现有的临床治疗相结合将产生更有效的I/R损伤治疗方法。本综述旨在提供该研究领域获得的新研究成果。希望关于这一主题的新研究不仅能对miRNA在I/R损伤中的病理生理学产生新的见解,还能为miRNA在I/R中的临床应用提供依据。